INS and type 1 diabetes mellitus: These results are consistent with an analysis of randomized clinical trials comparing CSII with MDI in subjects with T1D in which CSII was shown to lead to statistically lower HbA1c values regardless of whether regular human insulin or rapid‐acting analogue insulin was utilized.7